Pegasys approved for HIV/hepatitis C coinfection in Europe and US

In February, PegInterferon (Pegysys, Roche) was approved for treatment for hepatitis C in clincally stable patients that are coinfected with HIV. The European and US decision came within a few weeks of each other.

Approval was based on results on the APRICOT study, reported last year in full in NEJM. [1]

Source: Roche press release.


  1. Torriani FJ et al. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis c Virus Infection in HIV-Infected Patients. N Engl. J Med. 2204;351(5): 438-450.

Links to other websites are current at date of posting but not maintained.